文献速递慢性静脉疾病

聚多卡醇静脉微泡沫与医师配制泡沫硬化治疗主干静脉曲张的系统评价与网状Meta分析

Comparison of polidocanol endovenous microfoam (Varithena) to physician-compounded foam in sclerotherapy treatment of truncal varicosities: A systematic review and network meta-analysis.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2026-02-26

本研究通过系统评价与网状Meta分析比较Varithena与医师配制泡沫(PCF)治疗主干静脉曲张的疗效。纳入6项随机对照试验共1726例患者,中位随访39周。Varithena与PCF在闭塞率(RR 1.12,95%CI 0.93-1.35)和不良事件发生率(RR 2.89,95%CI 0.64-12.97)上均无显著差异;手术剥脱和静脉腔内激光消融的闭塞率显著高于泡沫硬化治疗。

要点

  • Varithena与PCF在主干静脉曲张闭塞率上无显著差异。
  • 两组不良事件发生率相似,无显著差异。
  • 手术剥脱和EVLA闭塞率显著高于泡沫硬化治疗。

核心结论

  • 在大隐静脉曲张患者中,无证据表明Varithena优于PCF或并发症更少。
  • 需进一步试验明确Varithena在静脉曲张治疗中的角色,尤其考虑更便宜的替代方案。

研究设计与样本

  • 系统评价与网状Meta分析,遵循PRISMA和Meta-Analysis指南,注册于PROSPERO(CRD42024494805)。
  • 检索Medline和EMBASE数据库自建库至2025年6月17日,由两名评价者独立筛选。
  • 纳入报告泡沫硬化治疗后主干静脉曲张闭塞率的随机对照试验。
  • 共纳入6项随机对照试验,总计1726例患者。

主要发现

  • 完全闭塞定义为双功超声显示隐股交界反流消失或大隐静脉闭塞。
  • 中位随访39周(范围12-52周)。
  • Varithena与PCF随访时闭塞率无显著差异(RR 1.12;95%CI 0.93-1.35;I2=71%)。
  • Varithena与PCF不良事件发生率相似(RR 2.89;95%CI 0.64-12.97;I2=0%)。
  • 与泡沫硬化治疗相比,手术剥脱和静脉腔内激光消融随访时闭塞率显著更高(RR 1.32,95%CI 1.18-1.47,I2=71%;RR 1.33,95%CI 1.18-1.49,I2=71%)。

临床怎么用

  • 对于主干静脉曲张,Varithena与PCF疗效和安全性相当,选择时需考虑成本效益。
  • 泡沫硬化治疗的闭塞率低于手术剥脱和EVLA,临床决策应结合患者具体情况。

局限性

  • 随访时间中位39周,缺乏长期结局数据。
  • 部分分析存在显著异质性(I2=71%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Commercial premixed foam sclerosants such as Varithena, a polidocanol endovenous microfoam, have been developed and marketed as better alternatives to physician-compounded foams (PCFs). The aim of this study was to evaluate the efficacy of Varithena compared with PCFs in foam sclerotherapy for the treatment of truncal varicose veins. METHODS: A systematic review was performed according to PRISMA and Meta-Analysis guidelines with a registered protocol (PROSPERO: CRD42024494805) using Medline and EMBASE databases from inception to June 17, 2025, by two reviewers. Randomized controlled trials that reported on occlusion rates after truncal varicose vein treatment with foam sclerotherapy were included. A network meta-analysis was performed. RESULTS: Six randomized controlled trials with a total of 1726 patients were identified. Complete occlusion was defined as elimination of saphenofemoral junction reflux or occlusion of the saphenous vein on duplex imaging. The median follow-up was 39 weeks (range, 12-52 weeks). No significant difference was observed between Varithena and PCF with respect to occlusion rates at follow-up (risk ratio [RR], 1.12; 95% confidence interval [CI], 0.93-1.35; I2 =71%). Moreover, similar rates of adverse events were observed between the Varithena and PCF groups (RR, 2.89; 95% CI, 0.64-12.97; I2 = 0%). Compared to foam sclerotherapy, surgical removal and endovenous laser ablation showed a significantly higher occlusion rate at follow-up (RR 1.32, 95% CI 1.18-1.47, I2=71% and RR 1.33, 95% CI 1.18-1.49, I2=71%, respectively). CONCLUSIONS: In patients with saphenous varices, there was no indication that Varithena was superior to or associated with fewer complications than PCFs Further trials are required to define the role of Varithena in the treatment of varicose veins, especially within the context of less expensive alternatives.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Chen R, Soh CL, Salih M, et al. Comparison of polidocanol endovenous microfoam (Varithena) to physician-compounded foam in sclerotherapy treatment of truncal varicosities: A systematic review and network meta-analysis. J Vasc Surg Venous Lymphat Disord. 2026. PMID: 41763540. doi:10.1016/j.jvsv.2026.102460

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。